|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas显示文摘 | Jeffrey R. Infante Bradley G. Somer Joon Oh Park Chung-Pin Li Max E. Scheulen Saifuddin M. Kasubhai Do-Youn Oh Yuan Liu Suman Redhu Klaudia Steplewski Ngocdiep Le | 2014 | European Journal of Cancer2014，，： | 4 |
| 2 | Clinical benefit and health - related quality of life assessment in patients treated with cisplatin/S - 1 versus cisplati~5 - FU : Secondary end point results from the first -line advanced gastric cancer study (FLAGS) 显示文摘 | BODOKY G SCHEULEN M E RIVERA F | 2015 | J Gastrointest Cancer2015，46，2： | 1 |
| 3 | Tolllikereceptor 9 agonists as cancer therapeutics显示文摘 | Holtick U Scheulen ME von Bergwelt-Baildon MS | 2011 | Expert Opin Investig Drugs2011，20，3： | 1 |
| 4 | The Ras-RafMEK-ERK pathway in the treatment of cancer显示文摘 | Hilger RA Scheulen ME Strumberg D | 2002 | Onkologie2002，25，6： | 1 |
| 5 | Phase 2 safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer-Interim analysis显示文摘 | Chan S Johnston SR Scheulen ME | 2002 | Breast Cancer Research and Treatment2002，76，1： | 1 |
| 6 | Improved immume reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow显示文摘 | Ottinger HD Beelen DW Scheulen B | 1996 | Blood1996，88，7： | 1 |
| 7 | Phase Ⅱ study of nimotuzumab,a humanized monoclonal anti-epi- dermal growth factor receptor (EGFR) antibody in patients with locally advanced or metastatic pancreatic cancer显示文摘 | Strumberg D Schuhheis B Scheulen ME | 2012 | Invest New Drugs2012，30，3： | 1 |
| 8 | The Ras-Raf-MEK-ERK pathway in the treatment of cancer 显示文摘 | Hilger RA Scheulen ME Strmnberg D | 2002 | Oncology2002，25，6： | 1 |
| 9 | The detection of WF1 transcripts is not associated with an ingene WTI product 显示文摘 | Elmaagacli AH Bellen DW Scheulen B | 2005 | Expert Rev Vaccines2005，4，4： | 1 |
| 10 | Toll-like receptor 9 agonists as cancer therapeutics显示文摘 | Udo Holtick Max E Scheulen Michael S von Bergwelt-Baildon Martin R Weihrauch | 2011 | Expert Opinion on Investigational Drugs2011，，3： | 1 |
| 11 | Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study 显示文摘 | Strumberg D Scheulen M E Schultheis B | 2012 | Br J Cancer2012，106，11： | 1 |
| 12 | High Precise Reflector and Mirror in Fiber-Composite Technology 显示文摘 | Bernd Abt Gunter Helwig Dietmar Scheulen | | Dornier-System GmbH :427 - 4300，，： | 1 |
| 13 | The Ras-Raf-MEK- ERK pathway in the treatment of cancer显示文摘 | Hilger RA Scheulen ME Strumberg D | 2002 | Onkologie2002，25，6： | 1 |
| 14 | Phase II study of temsirolimus ( CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or meta- static breast cancer 显示文摘 | Chan S Scheulen ME Johnston S | 2005 | J Clin Oncol2005，23，23： | 1 |
| 15 | Recent de- velopments of advanced structures for space optics at astrium 显示文摘 | STUTE T WULZ G SCHEULEN D | | SPIE0，5179，： | 1 |
| 16 | The Ras - Raf - MEK - ERK pathway in the treatment of cancer 显示文摘 | Hilger RA Scheulen ME Strumberg D | 2002 | Onkologie2002，25，6： | 1 |
| 17 | A phase I dose-escalation study of BI 811283,an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors 显示文摘 | MROSS K B SCHEULEN M E FROST A | 2010 | J Clin Oncol2010，28，15： | 1 |
| 18 | Toll-like receptor 9 agonists as cancer therapeutics 显示文摘 | Holtick U Scheulen ME von Bergweh-Baildon MS | 2011 | Expert Opin InvestigDrugs2011，20，3： | 1 |
| 19 | A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15, every four weeks in patients with advanced solid tumors 显示文摘 | SCHEULEN M E MROSS K B RICHLY H | 2010 | J Clin Oncol2010，28，15： | 1 |
| 20 | Impact of ambulance diversion policies in urban, suburban, and rural areas of Central Maryland显示文摘 | Scheulen J J Li G Kelen G D | 2001 | Acad Emerg Med2001，8，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员